Lakefront Biotherapeutics NV (LKFT) Live Share Price, Invest From India

Lakefront Biotherapeutics NV Stock Performance

as on May 14, 2026 at 2:15 pm IST

Day's Low
Day's High
$27.22
Day's Price Range
$28.32
$28.14
3.27%
Downside
0.64%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$28.14
100.00%
Downside
-100.00%
Upside

Lakefront Biotherapeutics NV share price movements today

Previous Close: $27.33
Open: $27.32
Volume: 401.9K
Day's Low - High: $27.22 - $28.32

Lakefront Biotherapeutics NV Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Lakefront Biotherapeutics NV Stock Fundamentals & Key Indicators

Check Lakefront Biotherapeutics NV market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.8B

EPS (TTM)

-2.26

Dividend Yield

0.00%

PE Ratio (TTM)

3.14

PEG Ratio

Return On Equity TTM

16.26%

Lakefront Biotherapeutics NV vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Lakefront Biotherapeutics NV with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Lakefront Biotherapeutics NV	NA	$1.8B	NA	3.14	46.83%
Alnylam Pharmaceuticals Inc	BUY	$38.0B	115.2%	71.39	12.55%
BeiGene, Ltd.	NA	$32.7B	NA	71.44	8.94%
Vertex Pharmaceuticals Inc	BUY	$110.4B	106.5%	25.84	35.51%
Regeneron Pharmaceuticals Inc	BUY	$74.7B	40.03%	17.39	29.65%

Indian Investors' Interest in Lakefront Biotherapeutics NV Stock

Search interest for Lakefront Biotherapeutics NV Stock has increased by 20% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 14, 2026 to May 14, 2026

Change:20% versus previous 30 day period

Lakefront Biotherapeutics NV Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	81	65	71	900	6
Gross Profit	66	60	60	900	1
Operating Income	-158	-57	-41	758	-63
EBITDA	-	-101	2	560	-63
Interest Expense	-	-	-	-	-
Depreciation	-	-	-	-	-
Income Before Tax	-156	-104	-221	783	13
Income Tax Expense	-	0	-17	0	0
Net Income	-165	-105	-202	782	14
Net Profit Margin	-204.60%	-161.97%	-284.02%	86.83%	223.61%

Lakefront Biotherapeutics NV Annual Profit & Loss

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	255	261	288	1,112
Gross Profit	255	261	251	1,082
Operating Income	-131	-88	-188	501
EBITDA	-	-	-	358
Interest Expense	9	1	0	2
Depreciation	65	43	45	55
Income Before Tax	-70	5	-3	300
Income Tax Expense	-	-	-	-18
Net Income	-230	230	77	320
Net Profit Margin	-90.36%	88.31%	26.88%	28.85%

Lakefront Biotherapeutics NV Quarterly Cash Flow

All numbers in Millions USD

	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-105	-202	782	14
Operating Cash Flow	-108	-62	-47	-82
Investing Cash Flow	74	56	72	61
Financing Cash Flow	0	-1	0	0
Change in Cash	-36	-7	23	-21

Lakefront Biotherapeutics NV Annual Cash Flow

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Net Income	211	74	320
Operating Cash Flow	-405	-320	-257
Investing Cash Flow	-	-	288
Financing Cash Flow	-5	-4	-3
Change in Cash	-339	-104	23

Insights on Lakefront Biotherapeutics NV

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 32.2% return, outperforming this stock by 64.7%
NO EFFECT
Against Peers
In the last 1 year, BeOne Medicines Ltd has given 43.2% return, outperforming this stock by 40.1%
NEGATIVE IMPACT
Price Dip
In the last 3 months, LKFT stock has moved down by -19.4%

About Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Organisation	Lakefront Biotherapeutics NV
Headquarters	SchaliEnhoevedreef 20 T, Mechelen, Belgium, 2800
Industry	Biotechnology
CEO	Mr. Henry Gosebruch
E-voting on shares	Click here to vote

Key Management of Lakefront Biotherapeutics NV

Name	Title
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.	Head of Investor Relations
Marieke Vermeersch	Head of Corporate Communication
Ms. Annelies Missotten	Executive Officer
Dr. Jeevan Shetty	Head of Clinical Development Oncology
Mr. Henry Gosebruch	CEO & Executive Director
Mr. Aaron L. Cox	Chief Financial Officer
Mr. Fred W. Blakeslee II	Executive VP & General Counsel
Ms. Tania Philipp	Chief Human Resources Officer
Ruiz Astigarraga	Head of Manufacturing Cell Therapy
Dr. John W. Mellors M.D.	Head of Cell & Antibody Therapy Discovery

FAQs

What is Lakefront Biotherapeutics NV share price today?

Lakefront Biotherapeutics NV share price today is $28.14 as on May 14, 2026 at 8:45 am IST at the close of the market. Lakefront Biotherapeutics NV share today touched a day high of $28.32 and a low of $27.22.

What is the 52 week high and 52 week low for Lakefront Biotherapeutics NV share?

Lakefront Biotherapeutics NV share touched a 52 week high of $ on January 1, 1970 and a 52 week low of $ on January 1, 1970. Lakefront Biotherapeutics NV stock price today i.e. May 14, 2026 at 8:45 am IST is closed at $28.14,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Lakefront Biotherapeutics NV's market capitalisation today?

Lakefront Biotherapeutics NV market capitalisation is $0.00T as on May 14, 2026 at 8:45 am IST.

How to invest in Lakefront Biotherapeutics NV Stock (LKFT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Lakefront Biotherapeutics NV on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lakefront Biotherapeutics NV Shares that will get you 0.0533 shares as per Lakefront Biotherapeutics NV share price of $28.14 per share as on May 14, 2026 at 8:45 am IST.

What is the minimum amount required to buy Lakefront Biotherapeutics NV Stock (LKFT) from India?

Indian investors can start investing in Lakefront Biotherapeutics NV (LKFT) shares with as little as ₹95.705 or $1 (as of May 14, 2026 at 1:38 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹957.05 in Lakefront Biotherapeutics NV stock (as per the Rupee-Dollar exchange rate as on May 14, 2026 at 1:38 pm IST). Based on Lakefront Biotherapeutics NV share’s latest price of $28.14 as on May 14, 2026 at 8:45 am IST, you will get 0.3554 shares of Lakefront Biotherapeutics NV. Learn more about fractional shares .